Post by Evernorth Health Services

By 2034, 79 additional gene and cell therapies are expected to be approved in the U.S. — building on a pipeline of 4,164+ therapies currently in development. These breakthroughs can be life-changing for patients, but they also require coordinated pathways so care teams can navigate access steps, site-of-care logistics, and reimbursement without avoidable delays. Read the article to learn more about the expanding gene and cell therapy pipeline and why patient-centered, clinically led coordination is essential to help eligible patients start therapy at the right time. https://lnkd.in/gmpsw7qd